Adaptimmune is an Oxford, UK-based biotechnology company that focuses on the use of T-cell therapy to treat cancer and infectious disease. Its therapies work by re-engineering the patient’s own T-cells to target and destroy cancerous or infected cells. The company is running trials across the United States in multiple myeloma, melanoma, sarcoma and ovarian cancer. Adaptimmune intends to use the $104m raised to advance its programs into clinical trials against multiple types of cancer. Leadership includes Dr. Jonathan Knowles (Chairman) and James Noble (Chief Executive Officer). The company also signed a deal with GlaxoSmithKline worth up to $350m.

Total raised

$104M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2014